Loading
A phase 1/2 trial of Anvumetostat and Docetaxel in advanced solid tumours, run by Amgen, active and no longer recruiting.
A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101) is a phase 1/2 interventional study registered as NCT05094336 by Amgen, with 329 participants enrolled, started 2022-02-01 and due to reach its primary completion in 2026-11-30. Interventions recorded: Anvumetostat, Docetaxel and Comparator Anvumetostat Test Tablet.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Anvumetostat, Amgen and the tag pipeline.
Shares Docetaxel, Metastatic cancer (cancer that has spread), Cytotoxic chemotherapy and the tag pipeline.
Shares Docetaxel, Metastatic cancer (cancer that has spread), Cytotoxic chemotherapy and the tag pipeline.
Shares Docetaxel, Cytotoxic chemotherapy and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Cytotoxic chemotherapy and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Cytotoxic chemotherapy and the tag pipeline.
Shares Docetaxel, Cytotoxic chemotherapy and the tag pipeline.
Shares Docetaxel, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/